related documents
- A phase II study evaluating the safety and efficacy of patupilone in patients with platinum refractory/resistant ovarian, primary fallopian, or peritoneal cancer Conference Paper
- A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: Results after completion of stage I: A trial of the Princess Margaret Hospital Phase II Consortium Conference Paper
- A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer Conference Paper
- A phase II study of patupilone in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel Conference Paper
- A phase II study of single agent abraxane as second-line therapy in patients with advanced urothelial carcinoma Conference Paper
- A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the PMH Phase II Consortium Conference Paper
- A phase II trial of voreloxin in women with platinum-resistant ovarian cancer Conference Paper
- A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer Conference Paper
- Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF Conference Paper
- Comparison of randomized phase II studies (RP2s) and subsequent randomized controlled studies (RCTs) using identical systemic therapies Conference Paper
- Correlation of N-telopeptide of type I collagen (NTX) with survival and fractures in patients (pts) with bone metastases from renal cell carcinoma (RCC) Conference Paper
- Cost-effectiveness analysis of oncotype DX-guided treatment in early breast cancer Conference Paper
- Cost-effectiveness of cetuximab for the first-line treatment of squamous cell carcinoma of the head and neck (SCCHN) in Canada Conference Paper
- Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: A phase II randomized study Conference Paper
- Differences in uptake of postoperative adjuvant chemotherapy for lung cancer: Results from the Project for an Ontario Women's Health Evidence-Based Report Card (POWER) study Conference Paper
- Economic guidelines for oncology products: Adaptation of the Canadian Agency for Drugs and Technologies in Health (CADTH) technology assessment guidance document Conference Paper
- Effect of adjuvant chemotherapy on bone resorption marker beta C-telopeptide (B-CTX) in postmenopausal women Conference Paper
- Effect of geographic distance from a cancer centre on choice of systemic therapy in metastatic colorectal cancer Conference Paper
- Impact of positron emission tomography (PET) in stage III non-small cell lung cancer (NSCLC): A prospective randomized trial (PET START) Conference Paper
- Importance of stratification when measuring quality of care: Results from the Project for an Ontario Women's Health Evidence-Based Report Card (POWER) study Conference Paper
- Integration between primary care providers and the cancer system: Gaps and opportunities Conference Paper
- Interim analysis of a phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC) Conference Paper
- Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer Conference Paper
- OGX-427, a 2 ' methoxyethyl antisense oligonucleotide (ASO), against HSP27: Results of a first-in-human trial Conference Paper
- PET-CT compared to invasive mediastinal staging in non-small cell lung cancer (NSCLC) Conference Paper
- Phase I study of intravenous decitabine in combination with oral vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas (NHL) Conference Paper
- Phase II study of AVR118 in the management of cancer related anorexia/cachexia Conference Paper
- Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC) Conference Paper
- Predictors of recurrent thrombosis and anticoagulant-related bleeding in patients with cancer Conference Paper
- Primary tumor and patient characteristics in breast cancer as predictors of adjuvant chemotherapy regimen: A regression model Conference Paper
- Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer Conference Paper
- Safety and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): Analysis of MO19391 according to CT Conference Paper
- Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial Conference Paper
- The McGill Cancer Nutrition and Rehabilitation Program Conference Paper
- The management of dysphagia in esophageal cancer patients undergoing neoadjuvant chemotherapy: Is invasive tube feeding required? Conference Paper
- Tolerability and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) in elderly patients with advanced breast cancer (aBC): Subpopulation analysis of the MO19391 study Conference Paper
- Treatment and outcome of patients with brain metastases from non-small cell lung cancer (NSCLC) Conference Paper
- Trends in the application of dynamic allocation methods in multiarm cancer clinical trials Conference Paper
- Two-years biochemical failure-free survival following high intensity focused ultrasound (HIFU) for localized prostate cancer: Prospective single center study of 196 patients Conference Paper
- Willingness of breast cancer survivors to participate in a randomized controlled trial (RCT) of digital mammography with or without magnetic resonance imaging (MRI) as breast cancer (BC) surveillance: A feasiblity study Conference Paper